NasVax develops improved vaccines and immunotherapeutic products. The company has four distinct product areas: i. oral anti-CD3 monoclonal antibody immunotherapeutic; ii. VaxiSome® technology, which is an adjuvant-delivery system for enhancing the immunogenicity of vaccines and immunotherapeutics; iii. group-common pneumococcal vaccine, which is a protein-based vaccine that could become the field’s third-generation product; and iv. BBS1-based immunotherapeutics for Alzheimer’s disease.
View Top Employees from Nasvax| Website | http://www.nasvax.com |
| Revenue | $5.5 million |
| Employees | 5 (5 on RocketReach) |
| Founded | 2004 |
| Phone | (408) 236-7333 |
| Technologies | |
| Industry | Biotechnology, Business Services General, Vaccines & Immunotherapeutic Products, Business Services |
| Competitors | Compass Therapeutics Inc., Intensity Therapeutics, Inc., Madison Vaccines Inc |
| SIC | SIC Code 283 Companies, SIC Code 737 Companies, SIC Code 28 Companies, SIC Code 73 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 32 Companies |
Looking for a particular Nasvax employee's phone or email?
Nasvax Questions
The Nasvax annual revenue was $5.5 million in 2024.
Michael Tal is the R and D Director of Nasvax.
5 people are employed at Nasvax.
The NAICS codes for Nasvax are [325, 3254, 54, 541, 32].
The SIC codes for Nasvax are [283, 737, 28, 73].
Top Nasvax Employees
-
13
-
13
-
11
Related Companies
